Focused on developing and commercializing therapies for serious bacterial infections, the company built its business around hospital-administered antibiotics used to treat drug-resistant pathogens. Its flagship product, Cubicin (daptomycin), became a widely used treatment for complicated skin infect...
No congressional trades have been disclosed for 467037 (CBST) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.